¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¾Æ»êº´¿ø Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À° : 2023-06-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

¼­¿ï¾Æ»êº´¿ø Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À° : 2023-06-10
±³À°ÀÏÀÚ : 2023-06-10
±³À°Àå¼Ò : ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç

±³À°ÁÖÁ¦ : Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À°

ÁÖÃÖ±â°ü : ¼­¿ï¾Æ»êº´¿ø
´ã´çÀÚ : ¿ì¹Ì°æ
¿¬¶ôó : 02-3010-4560  

À̸ÞÀÏ : rainmk@rainmk@amc.seoul.kr

±³À°Á¾·ù : º´¸®°ú

Âü¼®¿¹»óÀÎ : 90¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í "1. Àü°øÀÇ/±ºÀÇ°ü/¿¬±¸¿ø   »çÀüÁ¢¼ö 20,000¿ø ÇöÀåÁ¢¼ö 30,000¿ø

2. Àü¹®ÀÇ /¹Ú»ç  »çÀüÁ¢¼ö 40,000¿ø  ÇöÀåÁ¢¼ö 50,000¿ø"

±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 10:00~10:40 Clinical Application of ctDNA in Medical Oncology ±è»óÀ§(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 10:40~11:40 Strategic development of anti-cancer immunotherapy using single cell RNA sequencin ÀÌÇý¿Á(°¡Å縯´ëÇб³)

½Ä»ç 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 11:40~13:10 Á¡½É ()

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 13:10~13:40 Liquid Biopsy based Clinical NGS at ASAN Pathology õ¼º¹Î(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 13:40~14:10 The age of whole genome sequencing: ready yet in clinics? ¼ºÃ¢¿Á(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 14:10~14:40 Longitudinal NGS analysis and early drug development À±½Å±³(¼­¿ï¾Æ»êº´¿ø)

ÈÞ½Ä 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 14:40~15:00 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 15:00~15:30 Digging out useful information through NGS in cancer of unknown primary setting ±èÁöÈÆ(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 15:30~16:00 Clinical significance of concurrent genomic alterations in EGFR-mutant lung adenocarcinoma ȲÈñ»ó(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 16:00~16:30 Detection and interpretation of non-canonical fusions ¼ÛÀÎÇý(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 16:30~17:00 Efforts to utilize clinical NGS data in AMC ±è´öÈÆ(¼­¿ï¾Æ»êº´¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¾Æ»êº´¿ø Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À° : 2023-06-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³âµµ Á¦21ȸ ¼­¿ï½Ã ³²¼­ 7°³±¸ ÀÇ»çȸ ÇÕµ¿ Çмú´ëȸ : 2023-06-10
´ÙÀ½±Û Á¦7ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2023-06-10
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
528 ¼­¿ï ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç ½ÉÆ÷Áö¾ö : 2018-09-14 0 980 2018-08-22
527 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø ECHO SEOUL 2018 : 2018-09-14 0 537 2018-08-22
526 ¼­¿ï ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ : 2018-09-14 0 886 2018-08-22
525 ¼­¿ï ´ëÇѼҾƽŰæÇÐȸ µÎÅ뿬±¸È¸ ÇмúÁý´ãȸ : 2018-09-14 0 828 2018-08-22
524 ÀüºÏ ´ëÇÑÀÇ»çÇùȸ 2018 Àü¶óºÏµµ °øÁߺ¸°ÇÀÇ»ç Á÷¹«±³À° (2Â÷) : 2018-09-14 0 1,713 2018-08-22
523 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-14 0 779 2018-08-22
522 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Practical Disaster Preparedness - from Evidence to Practice : 2018-09-13 0 886 2018-08-22
521 ÀüºÏ 2018 Àü¶óºÏµµ °øÁߺ¸°ÇÀÇ»ç Á÷¹«±³À° (1Â÷) : 2018-09-13 0 1,117 2018-08-22
520 °æ±â °í·Á´ëÇб³ ¾È»êº´¿ø ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ Á¦77Â÷ ¿ù·ÊÁý´ãȸ : 2018-09-13 0 1,010 2018-08-22
519 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú 2Çбâ Áö¿ªÀÇ»çÁý´ãȸ : 2018-09-13 0 496 2018-08-22
518 ºÎ»ê ´ëÇÑ°ñ´ë»çÇÐȸ 2018³â ºÎ»ê,¿ï»ê,°æ³²Áöȸ Á¦2Â÷ Áý´ãȸ : 2018-09-12 0 714 2018-08-22
517 ±¤ÁÖ Á¶¼±´ëº´¿ø Á¦ 157Â÷ ´ëÇÑÇǺΰúÇÐȸ È£³²Áöȸ : 2018-09-12 0 815 2018-08-22
516 ÀÎõ ÀÎõ¼º¸ðº´¿ø ´ëÇÑÇǺΰúÇÐȸ Á¦39Â÷ ÀÎõÁöºÎȸ ÇмúÁý´ãȸ : 2018-09-12 0 2,777 2018-08-22
515 ÀÎõ ±æº´¿ø Çѱ¹¿©ÀÚÀÇ»çȸ ºñŸ¹ÎDÀÇ ÀÌÇØ¿Í ÀÓ»óÀû¿ë : 2018-09-12 0 1,437 2018-08-22
514 ¼­¿ï °¡Å縯´ëÇб³¿©Àǵµ¼º¸ðº´¿ø À̺ñÀÎÈÄ°ú Çù·Âº´ÀÇ¿ø °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-11 0 1,095 2018-08-22
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷